Literature DB >> 2828337

Coumarin and quinolone action in archaebacteria: evidence for the presence of a DNA gyrase-like enzyme.

M Sioud1, O Possot, C Elie, L Sibold, P Forterre.   

Abstract

The action of novobiocin and coumermycin (two coumarins which interact with the gyrB subunit of eubacterial DNA gyrase) and ciprofloxacin (a fluoroquinolone which interacts with the gyrA subunit of DNA gyrase) was tested on several archaebacteria, including five methanogens, two halobacteria, and a thermoacidophile. Most strains were sensitive to doses of coumarins (0.02 to 10 micrograms/ml) which specifically inhibit DNA gyrase in eubacteria. Ciprofloxacin inhibited growth of the haloalkaliphilic strain Natronobacterium gregoryi and of the methanogen Methanosarcina barkeri. In addition, ciprofloxacin partly relieved the sensitivity to coumarins (and vice versa). Novobiocin inhibited DNA replication in Halobacterium halobium rapidly and specifically. Topological analysis has shown that the 1.7-kilobase plasmid from Halobacterium sp. strain GRB is negatively supercoiled; this plasmid was relaxed after novobiocin treatment. These results support the existence in archaebacteria of a coumarin and quinolone target related to eubacterial DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828337      PMCID: PMC210746          DOI: 10.1128/jb.170.2.946-953.1988

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  25 in total

1.  The problems of eukaryotic and prokaryotic DNA packaging and in vivo conformation posed by superhelix density heterogeneity.

Authors:  M Shure; D E Pulleyblank; J Vinograd
Journal:  Nucleic Acids Res       Date:  1977       Impact factor: 16.971

Review 2.  Bacterial evolution.

Authors:  C R Woese
Journal:  Microbiol Rev       Date:  1987-06

3.  Ribosomal RNA phylogeny and the primary lines of evolutionary descent.

Authors:  N R Pace; G J Olsen; C R Woese
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

4.  Both DNA topoisomerases I and II relax 2 micron plasmid DNA in living yeast cells.

Authors:  R A Saavedra; J A Huberman
Journal:  Cell       Date:  1986-04-11       Impact factor: 41.582

5.  Eubacteria, halobacteria, and the origin of photosynthesis: the photocytes.

Authors:  J A Lake; M W Clark; E Henderson; S P Fay; M Oakes; A Scheinman; J P Thornber; R A Mah
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 6.  Biology of bacterial deoxyribonucleic acid topoisomerases.

Authors:  K Drlica
Journal:  Microbiol Rev       Date:  1984-12

7.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase.

Authors:  M Cotten; D Bresnahan; S Thompson; L Sealy; R Chalkley
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

9.  Mode of action of novobiocin in Escherichia coli.

Authors:  D H Smith; B D Davis
Journal:  J Bacteriol       Date:  1967-01       Impact factor: 3.490

10.  Aphidicolin inhibits growth and DNA synthesis in halophilic arachaebacteria.

Authors:  P Forterre; C Elie; M Kohiyama
Journal:  J Bacteriol       Date:  1984-08       Impact factor: 3.490

View more
  13 in total

1.  The complete genome of the crenarchaeon Sulfolobus solfataricus P2.

Authors:  Q She; R K Singh; F Confalonieri; Y Zivanovic; G Allard; M J Awayez; C C Chan-Weiher; I G Clausen; B A Curtis; A De Moors; G Erauso; C Fletcher; P M Gordon; I Heikamp-de Jong; A C Jeffries; C J Kozera; N Medina; X Peng; H P Thi-Ngoc; P Redder; M E Schenk; C Theriault; N Tolstrup; R L Charlebois; W F Doolittle; M Duguet; T Gaasterland; R A Garrett; M A Ragan; C W Sensen; J Van der Oost
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  Evidence that a plasmid from a hyperthermophilic archaebacterium is relaxed at physiological temperatures.

Authors:  F Charbonnier; G Erauso; T Barbeyron; D Prieur; P Forterre
Journal:  J Bacteriol       Date:  1992-10       Impact factor: 3.490

3.  A plasmid vector with a selectable marker for halophilic archaebacteria.

Authors:  M L Holmes; M L Dyall-Smith
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

4.  Mutations in DNA gyrase result in novobiocin resistance in halophilic archaebacteria.

Authors:  M L Holmes; M L Dyall-Smith
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

5.  The origin of a derived superkingdom: how a gram-positive bacterium crossed the desert to become an archaeon.

Authors:  Ruben E Valas; Philip E Bourne
Journal:  Biol Direct       Date:  2011-02-28       Impact factor: 4.540

6.  Effects of salt and temperature on plasmid topology in the halophilic archaeon Haloferax volcanii.

Authors:  F J Mojica; F Charbonnier; G Juez; F Rodríguez-Valera; P Forterre
Journal:  J Bacteriol       Date:  1994-08       Impact factor: 3.490

7.  Novobiocin induces accumulation of a single strand of plasmid pGRB-1 in the archaebacterium Halobacterium GRB.

Authors:  M Sioud; G Baldacci; P Forterre; A M de Recondo
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

8.  Local beneficial effect of coumarin in experimental peritonitis.

Authors:  T A Creagh; A L Leahy; E McNamara; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  1991-12       Impact factor: 1.568

9.  Anticoagulant-induced changes on antibiotic concentrations in the serum and bones.

Authors:  A Kotsiou; E Diamanti; A Potamianou; H Parara; J Vovou; C Perisanidis; C Tes; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

Review 10.  Phylogenomics of DNA topoisomerases: their origin and putative roles in the emergence of modern organisms.

Authors:  Patrick Forterre; Danièle Gadelle
Journal:  Nucleic Acids Res       Date:  2009-02-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.